Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Intercept Pharmaceuticals, Inc. and Genfit SA – Notable Market Players in Non-alcoholic steatohepatitis (NASH) Market
Growth of the global nonalcoholic steatohepatitis (NASH) market is majorly driven by rising prevalence of NASH and increasing initiatives for the awareness of NASH. However, lack of established guidelines in the diagnosis and withdrawal of drugs from seeking marketing authorization for NASH is hampering market growth.
The Non-alcoholic steatohepatitis (NASH) market is majorly comprised of top players involving Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the Non-alcoholic steatohepatitis (NASH) market:
| Year | News |
| Nov-2021 | GENFIT announced that its NIS4 technology has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis (NASH). |
| Jun-2021 | GENFIT announced poster presentation at two internationally-renown scientific and medical events in June 2021, including a thought-leadership documentary featuring Key Opinion Leaders (KOLs). These presentation is on the clinical performance of GENFIT’s proprietary diagnostic technology NIS4 in diagnosing at-risk NASH in patients with type 2 diabetes. |
| Jan-2022 | Galmed Pharmaceuticals Ltd. announced that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota. |
| Apr-2022 | Sandoz announced its extension of collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR). |
| Mar-2022 | Novartis announced that it has signed agreement with Carisma Therapeuticsto manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors. |
